切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2010, Vol. 04 ›› Issue (06) : 734 -740. doi: 10.3877/cma.j.issn.1674-0807.2010.06.017

实验研究

Pokemon mRNA与c-myc蛋白在乳腺癌组织中的表达及其相关性
崔明1, 付朝江1, 杨彦1, 冯雁康1, 刘嘉1   
  1. 1.650032 昆明,成都军区昆明总医院普通外科
  • 收稿日期:2009-08-12 出版日期:2010-12-01

Expressions of Pokemon mRNA and c-myc in breast carcinoma and their correlation

Ming CUI1, Chao-jiang FU1, Yan YANG1, Yan-kang FENG1, Jia LIU1   

  1. 1.Department of General Surgery,Kunming General Hospital of Chengdu Military Region,Kunming 650032,China
  • Received:2009-08-12 Published:2010-12-01
引用本文:

崔明, 付朝江, 杨彦, 冯雁康, 刘嘉. Pokemon mRNA与c-myc蛋白在乳腺癌组织中的表达及其相关性[J/OL]. 中华乳腺病杂志(电子版), 2010, 04(06): 734-740.

Ming CUI, Chao-jiang FU, Yan YANG, Yan-kang FENG, Jia LIU. Expressions of Pokemon mRNA and c-myc in breast carcinoma and their correlation[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2010, 04(06): 734-740.

目的

探讨人乳腺癌中原癌基因c-myc和Pokemon m RNA 在乳腺癌组织中的表达及其与乳腺癌发生、转移的关系。

方法

收集本院2008 年1 月至10 月45例浸润性导管癌组织标本、20例癌旁乳腺组织标本和20例正常乳腺组织标本,均为女性,年龄23~69岁。所有标本均经临床病理确诊。采用原位杂交法检测Pokemon m RNA 表达,采用免疫组织化学法检测c-myc表达。采用卡方检验和等级相关法进行统计分析。

结果

(1)Pokemon m RNA 的阳性表达率在乳腺癌组织、癌旁乳腺组织和正常乳腺组织中分别是71.11% (32/45),30.00% (6/20)和20.00% (4/20),3者间差异有统计学意义(P=0.000)。c-myc阳性表达率在乳腺癌组织、癌旁乳腺组织和正常乳腺组织中分别是86.67% (39/45),60.00% (12/20)和50.00% (10/20),3者间差异有统计学意义(P=0.004)。(2)乳腺癌细胞质Pokemon mRNA 表达和乳腺癌细胞质c-myc表达都与乳腺癌腋窝淋巴结转移有关(P=0.012,P=0.027)。(3)乳腺癌细胞质Pokemon m RNA 表达与c-myc表达有关联性(r=0.585,P<0.000)。

结论

Pokemon m RNA 和c-myc蛋白可能参与乳腺导管癌的发生和转移。Pokemon m RNA表达和c-myc表达两者间有相关性。

Objective

To explore the expressions of Pokemon m RNA and proto-oncogene c-myc in breast cancer and their relation with carcinogenesis and metastasis.

Methods

From January to October 2008,45 samples of invasive ductal carcinoma,20 samples of pericancer tissue and 20 samples of normal breast tissue were collected for the study.All study subjects were female,aged 23 to 69 years.All samples were confirmed pathologically.The expression of Pokemon m RNA was examined using in situ hybridization and the expression of c-myc was tested using immunohistochemistry.Chi-square test and Spearman's rank correlation coefficient were used for statistical analysis.

Results

(1)The rate of positive expression of plasma Pokemon m RNA in breast cancer tissue,pericancer tissue and normal breast tissue was 71.11% (32/45),30.00% (6/20)and 20.00% (4/20)respectively,with statistical difference between the three groups(P=0.000).The rate of positive expression of c-myc in breast cancer tissue,pericancer tissue and normal breast tissue was 86.67% (39/45),60.00% (12/20)and 50.00% (10/20)respectively,with statistical difference between the three groups (P =0.004).(2)The positive expressions of Pokemon m RNA and c-myc in breast cancer were correlated with breast cancer axillary lymph node metastasis(P=0.012,P=0.027).(3)There was a positive correlation between Pokemon mRNA and c-myc(r=0.585,P<0.000).

Conclusions

Pokemon m RNA and c-myc participate in the pathogenesis and metastasis of breast cancer,and there is a correlation between Pokemon m RNA and cmyc.

表1 Pokemon m RNA 和c-myc蛋白在乳腺癌、癌旁组织及正常乳腺组织中的表达
图1 乳腺浸润导管癌Pokemon m RNA 的阳性表达(原位杂交SP染色 ×200) Pokemon mRNA 阳性表达定位于癌细胞胞质
图2 乳腺浸润导管癌c-myc阳性表达(免疫组化SP染色 ×200) c-myc阳性表达定位于癌细胞胞质
表2 Pokemon m RNA 和c-myc蛋白的表达与乳腺癌临床病理特征的关系
表3 Pokenon mRNA和c-myc蛋白在乳腺癌中表达的关系
[1]
Hatakeyama S,Watanabe M,Fujii Y,et al.Targeted destruction of c-myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.Cancer Res,2005,65:7874-7879.
[2]
Hemann MT,Bric A,Teruya-Feldstein J,et al.Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.Nature,2005,436:787-789.
[3]
Maeda T,Hobbs RM,Merghoub T,et al.Role of the proto-oncogene Pokemon mRNA in cellular transformation and ARF repression.Nature,2005,433:278-285.
[4]
Morrison DJ,Pendergrast PS,Stavropoulos P,et al.FBI,a factor that binds to the HIV-1 inducer of short transcripts(IST),is a POZ domain protein.Nucleic Acid Res,1999,5:1251-1253.
[5]
Xiao Q,Claassen G,Shi J,et al.Transactivation-defective c-Myc retains the ability to regulate proliferation and apoptosis.Genes Dev,1998,12:3803-3808.
[6]
Pessler F,Pendergrast PS,Hernandez N.Purification and characterization of FBI-1:a cellular factor that binds to the human immunodeficiency virus type 1 inducer of short transcripts.Mol Cell Bio,1997,17:3786-3789.
[7]
Lee DK,Suh D,Edenberg HJ,et al.POZ domain transcription factor,FBI-1,represses transcription of ADH5/FDH by interacting with the zinc finger and interfering with DNA binding activity ofSp1.J Biol Chem,2002,277:26761-26766.
[8]
Cole MD,McMahon SB.The Myc oncoprotein:a critical evaluation of transactivation and target gene regulation.Oncogene,1999,18:2916-2919
[9]
Hemann MT,Bric A,Teruya-Feldstein J,et al.Evasion of the p53 tumour surveillance network by tumour derived MYC mutants.Nature,2005,436:787-789.
[10]
Corzo C,Corominas JM,Tusquets I,et al.The MYC oncogene in breast cancer progression:from benign epithelium to invasive carcinoma.Cancer Genet Cytogenet,2006,165:151-156.
[11]
White RA,Adkison LR,Dowler LL,et al.Chromosomal localization of the human gene encoding c-myc promoter binding protein(MPB1)to chromosome 1p35-pter.Genomics,1997,39:406-408.
[12]
Shanmugham R,Gopalan R,Shanthi P,et al.Tumor angiogenesis and C-myc expression in breast carcinomas.Indian J Pathol Microbiol,2004,47:340-342.
[1] 洪玮, 叶细容, 刘枝红, 杨银凤, 吕志红. 超声影像组学联合临床病理特征预测乳腺癌新辅助化疗完全病理缓解的价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 571-579.
[2] 赵阳, 肖迎聪, 巨艳, 党晓智, 蔡林利, 薛文欣, 李洋, 肖瑶, 郭妤绮, 宋宏萍. 自动乳腺超声联合免疫组化早期预测乳腺癌新辅助化疗病理完全缓解的临床价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(04): 361-369.
[3] 刘伟, 牛云峰, 安杰. LINC01232 通过miR-516a-5p/BCL9 轴促进三阴性乳腺癌的恶性进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 330-338.
[4] 杨柳, 宋振川, 王新乐. 乳腺癌改良根治术联合背阔肌复位的临床疗效评估[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 269-273.
[5] 张钊, 骆成玉, 张树琦, 何平, 李旭斌. 不同术式治疗早期乳腺癌的效果及并发症发生率、复发率比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 494-497.
[6] 宋佳, 汪波, 孙凯律, 商江峰, 吴旦平, 肇毅. 吲哚菁绿荧光显影联合亚甲蓝染色在乳腺癌前哨淋巴结活检中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 498-501.
[7] 孙建娜, 孔令军, 任崇禧, 穆坤, 王晓蕊. 266例首诊Ⅳ期乳腺癌手术患者预后分析[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 502-505.
[8] 唐丹萍, 王萍, 江孟蝶, 杨晓蓉. 自体脂肪移植在乳腺癌术后乳房重建的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 582-585.
[9] 黄程鑫, 陈莉, 刘伊楚, 王水良, 赖晓凤. OPA1 在乳腺癌组织的表达特征及在ER阳性乳腺癌细胞中的生物学功能研究[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(05): 275-284.
[10] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[11] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王帅, 张志远, 苏雨晴, 李雯雯, 王守凯, 刘琦, 李文涛. 孟德尔随机化及其在乳腺癌研究中的应用进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 671-676.
[15] 张梦婷, 穷拉姆, 色珍, 李逸群, 德庆旺姆. 西藏地区藏族乳腺癌新辅助化疗的真实世界研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 441-446.
阅读次数
全文


摘要